Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S

Jerald Sadoff(University of Maryland, Baltimore), Macaya Douoguih(University of Maryland, Baltimore), Georgi Shukarev(University of Maryland, Baltimore), Hanneke Schuitemaker(University of Maryland, Baltimore), Johan Vingerhoets(University of Maryland, Baltimore), Gert C. Scheper(University of Maryland, Baltimore), Beatriz Grinsztejn(University of Maryland, Baltimore), Paul Goepfert(University of Maryland, Baltimore), Edith Swann(National Institutes of Health), Kathleen M. Neuzil(University of Maryland, Baltimore), Frank Struyf(University of Maryland, Baltimore), Dan H. Barouch(Beth Israel Deaconess Medical Center), Jeffrey J. Stoddard(University of Maryland, Baltimore), Karin Hardt(University of Maryland, Baltimore), Ilse Van Dromme(University of Maryland, Baltimore), An Vandebosch(University of Maryland, Baltimore), Lawrence Corey(Emory University Hospital), Martin Ryser(University of Maryland, Baltimore), Javier Ruiz‐Guiñazú(University of Maryland, Baltimore), Merlin L. Robb(University of Maryland, Baltimore), Jerome Custers(Janssen (Netherlands)), Carla Truyers(University of Maryland, Baltimore), Mary Marovich(University of Maryland, Baltimore), Bart Spiessens(University of Maryland, Baltimore), Vicky Cárdenas(University of Maryland, Baltimore), Johan Van Hoof(University of Maryland, Baltimore), John J. Treanor(University of Maryland, Baltimore), Mathieu Le Gars(University of Maryland, Baltimore), Glenda Gray(South African Medical Research Council)

New England Journal of Medicine

February 9, 2022

Cited by 250

|New England Journal of Medicine|2021|2.6k

|Nature Reviews Disease Primers|2018|1.5k

|The Lancet|2004|1.3k

|New England Journal of Medicine|1990|1.3k

|Science|2020|1.1k

Related Papers